Trapoxin A is a cyclotetrapeptide and an HDAC (histone deacetylase) inhibitor. Trapoxin increases the level of chromatin acetylation associated with histone H3 at low nanomolar concentrations. Unlike the reversible HDAC inhibition induced by TCA, Trapoxin irreversibly inhibits HDAC activity in crude cell lysates and induces the accumulation of hyperacetylated core histones in a number of mammalian cell lines and tissues. Histone acetylation and methylation have been studied extensively for their anti-tumor activities in carcinogenesis and Trapoxin has been suggested as a potential anticancer agent for pre-clinical trials.
1. Fang, J.Y., and Lu, Y.Y., Effects of histone acetylation and DNA methylation on p21 (WAF1) regulation. World J. Gastroenterol. 8, 400-405, (2002) 2. Yoshida, M., et al., Trichostatin A and Trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17, 423-430, (1995) 3. Vigushin, D.M., and Coombes, R.C., Histone deacetylase inhibitors in cancer treatment. Anti-Cancer Drugs 13, 1-13, (2002)
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.